Beta Bionics Files for IPO

Ticker: BBNX · Form: S-1 · Filed: Jan 6, 2025 · CIK: 1674632

Beta Bionics, Inc S-1 Filing Summary
FieldDetail
CompanyBeta Bionics, Inc (BBNX)
Form TypeS-1
Filed DateJan 6, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$3.1 million, $16.7 million, $10.0 million, $19.9 m, $44.7 m
Sentimentneutral

Sentiment: neutral

Topics: ipo, registration-statement, medical-device

TL;DR

Beta Bionics is going public! S-1 filed Jan 6, 2025.

AI Summary

Beta Bionics, Inc. filed an S-1 registration statement with the SEC on January 6, 2025, to register securities for a proposed public offering. The company, headquartered in Irvine, California, is preparing to go public, with Sean Saint serving as President and CEO and Stephen Feider as CFO. The filing indicates the offering will commence as soon as practicable after the registration statement is declared effective.

Why It Matters

This S-1 filing marks Beta Bionics' official step towards becoming a publicly traded company, potentially impacting the medical device market and investor opportunities.

Risk Assessment

Risk Level: medium — As a company filing for an IPO, Beta Bionics faces inherent market risks and the uncertainties associated with transitioning to public ownership.

Key Players & Entities

  • Beta Bionics, Inc. (company) — Registrant
  • January 6, 2025 (date) — Filing date
  • Sean Saint (person) — President and Chief Executive Officer
  • Stephen Feider (person) — Chief Financial Officer
  • Irvine, California (location) — Principal executive offices
  • Carlos Ramirez (person) — Legal counsel
  • Mark Weeks (person) — Legal counsel
  • Charles S. Kim (person) — Legal counsel
  • Cooley LLP (company) — Legal counsel
  • Nathan Ajiashvili (person) — Legal counsel

FAQ

What is the primary purpose of this S-1 filing by Beta Bionics, Inc.?

The primary purpose is to register securities for a proposed public offering, allowing the company to sell shares to the public.

When was the S-1 registration statement filed with the SEC?

The S-1 registration statement was filed with the SEC on January 6, 2025.

Who are the key executives mentioned in the filing for Beta Bionics, Inc.?

Sean Saint is listed as President and Chief Executive Officer, and Stephen Feider is listed as Chief Financial Officer.

Where are Beta Bionics, Inc.'s principal executive offices located?

Beta Bionics, Inc.'s principal executive offices are located at 11 Hughes, Irvine, California 92618.

When does Beta Bionics, Inc. anticipate the proposed sale of securities to the public to commence?

The proposed sale of securities to the public is expected to commence as soon as practicable after this Registration Statement is declared effective.

Filing Stats: 4,561 words · 18 min read · ~15 pages · Grade level 15.6 · Accepted 2025-01-06 16:25:33

Key Financial Figures

  • $3.1 million — quarterly revenue has grown over 5xfrom $3.1 million for the quarter ended September 30, 202
  • $16.7 million — the quarter ended September 30, 2023 to $16.7 million for the quarter ended September 30, 202
  • $10.0 million — only 2x during the same time periodfrom $10.0 million to $19.9 million, respectively. Our r
  • $19.9 m — e same time periodfrom $10.0 million to $19.9 million, respectively. Our revenue for
  • $44.7 m — ine months ended September 30, 2024 was $44.7 million, more than 3.5x that of our annua
  • $12.0 million — than 3.5x that of our annual revenue of $12.0 million for the year ended December 31, 2023. O
  • $3.6 million — ine months ended September 30, 2023 was $3.6 million. Our net losses were $25.3 million for
  • $25.3 million — 3 was $3.6 million. Our net losses were $25.3 million for the nine months ended September 30,
  • $36.6 million — ine months ended September 30, 2023 and $36.6 million for the nine months ended September 30,
  • $11.0 million — ust 2023, which contributed a change of $11.0 million in the fair value of warrant liabilitie
  • $229.7 million — reflected in the accumulated deficit of $229.7 million and $278.6 million, as of December 31,
  • $278.6 m — cumulated deficit of $229.7 million and $278.6 million, as of December 31, 2023 and Sept
  • $6 b — s in the United States is approximately $6 billion, which is comprised of the 3
  • $2 billion — 3 Table of Contents approximately $2 billion total addressable market of existing pu
  • $4 billion — isting pump users and the approximately $4 billion total addressable market of potential n

Filing Documents

Risk Factors

Risk Factors 22 Special Note Regarding Forward-Looking Statements 93 Market, Industry and Other Data 95 Dividend Policy 96

Use of Proceeds

Use of Proceeds 97 Capitalization 98

Managements Discussion and Analysis of Financial Condition and Results

Managements Discussion and Analysis of Financial Condition and Results of Operations 105

Business

Business 136 Management 201 Executive and Director Compensation 211 Certain Relationships and Related Party Transactions 228 Principal and Selling Stockholders 233

Description of Capital Stock

Description of Capital Stock 237 Shares Eligible for Future Sale 244 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders of Our Common Stock 247

Underwriting

Underwriting 251 Legal Matters 261 Experts 261 Where You Can Find More Information 261 Index to Financial Statements F-1 Neither we, the selling stockholders nor the underwriters have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. Neither we, the selling stockholders nor the underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We, the selling stockholders and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, or other earlier date stated in this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: neither we, the selling stockholders nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in o

View Full Filing

View this S-1 filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.